TL;DR
Anthropic has been secretly running a robotically automated, AI-operated biology wet lab in the Bay Area, revealed the same week it published a bioweapons safety report and its CEO called for pausing AI development.
What happened
- Anthropic's Bay Area wet lab was uncovered by Reuters via two anonymous sources and confirmed by the company's head of life sciences, Eric Kauderer-Abrams.
- The lab uses Claude AI to coordinate robotic lab assistants performing biology experiments with minimal human intervention.
- Kauderer-Abrams confirmed: "We absolutely are doing that today," framing it as early-stage automation of lab execution.
- The lab conducts in vitro biology work, building on protein-design research Anthropic touted earlier in 2025, but a spokesperson said it is not specifically pursuing drug discovery.
- Anthropic says it will stop short of clinical trials, avoiding direct competition with pharmaceutical companies that are prospective customers.
Why it matters
- The disclosure lands one week after Anthropic published a report on shutting down suspected bioweapons development by Claude users, creating a stark credibility gap: the company flagged external bio risks while concealing its own bio lab.
- CEO Dario Amodei cited AI-assisted bioterrorism as a civilizational threat in a weekend blog post calling for a development pause, without mentioning the lab.
- The dual-use risk is real: MIT synthetic biologist Kevin Esvelt warned this week that an AI chatbot suggested to him "a novel form of bioweapon" he "hadn't realized was possible," underscoring how biology-trained models blur the line between pharma R&D and weapons research.
- Amodei has publicly argued AI could compress 50 to 100 years of biological progress into 5 to 10 years, signaling this lab is a strategic bet, not a side project.
- If successful, Anthropic positions itself as both the infrastructure and the operator of AI-driven biotech, a vertical integration move that threatens pure-play drug discovery AI firms.
What to watch next
- Whether Anthropic discloses the lab's scope and safety protocols publicly, or whether regulatory scrutiny forces transparency before the company chooses to offer it.
- How pharmaceutical partners and biosafety regulators respond: the line between drug discovery and dual-use research will become a policy flashpoint as more AI labs enter wet-lab biology.
- Whether Amodei's "pacing the frontier" framing holds investor confidence while the company simultaneously accelerates autonomous biological research, or whether the contradiction fractures Anthropic's safety-first brand.
Originally published on Present of AI, a daily source-linked AI news timeline. Read the full timeline or browse the open dataset.